Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emergent Biosolutions ( (EBS) ) has issued an announcement.
On August 29, 2025, Emergent BioSolutions received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of CYFENDUS™, an anthrax vaccine. This contract, part of an ongoing agreement since 2016, underscores Emergent’s commitment to supporting U.S. national security priorities by ensuring the availability of medical countermeasures against anthrax threats. The deliveries are expected to start within the current calendar year and conclude by March 2026, highlighting Emergent’s strategic role in biodefense.
The most recent analyst rating on (EBS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.
Spark’s Take on EBS Stock
According to Spark, TipRanks’ AI Analyst, EBS is a Neutral.
Emergent Biosolutions’ overall stock score is driven by a strong valuation and positive earnings call sentiment, indicating potential for recovery. However, financial performance challenges and legal proceedings weigh on the score. Technical indicators show positive momentum, but caution is advised due to overbought signals.
To see Spark’s full report on EBS stock, click here.
More about Emergent Biosolutions
Emergent BioSolutions is a company focused on delivering protective and life-saving solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies. The company has been operational for over 25 years, preparing those responsible for public health protection.
Average Trading Volume: 1,294,509
Technical Sentiment Signal: Buy
Current Market Cap: $407.1M
Find detailed analytics on EBS stock on TipRanks’ Stock Analysis page.